{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T04:30:23Z","timestamp":1794717023170,"version":"4.9.1"},"reference-count":7,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2003,12,22]],"date-time":"2003-12-22T00:00:00Z","timestamp":1072051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2004,1]]},"abstract":"<jats:title>Abstract:<\/jats:title><jats:p><jats:bold>Introduction:\u2002<\/jats:bold> S\u00e9zary syndrome (SS) is a cutaneous T\u2010cell lymphoma characterized by erythroderma, lymphadenopathy and circulating atypical T cells. Median survival after diagnosis is 10\u2003yr, with chemotherapy resistance being a major problem in advanced disease. Alemtuzumab (Campath\u20101H) is a monoclonal antibody directed against the lymphocytic antigen CD52, expressed on B\u2010 and T\u2010cells. Alemtuzumab is approved for relapsing chronic B\u2010cell leukemia and seems to be active also in T\u2010cell lymphomas such as T\u2010cell prolymphocytic lymphoma, SS and mycosis fungiodes.<\/jats:p><jats:p><jats:bold>Case history:\u2002<\/jats:bold> A 32\u2010yr\u2010old male patient presented with advanced stage, extensively pretreated SS with heavily itching erythroderma, peripheral lymphadenopathy, circulating S\u00e9zary cells and bone marrow infiltration. The disease had not responded to PUVA\/interferon\u2010<jats:italic>\u03b1<\/jats:italic> and progressed on chemotherapy with CHOP, 2\u2010CDA, vinorelbine, etoposide and liposomal doxorubicin. Following treatment with alemtuzumab (30\u2003mg i.v. three times per week for 10\u2003wk), itching resolved rapidly and an almost complete remission was achieved within 3\u2003months after starting this treatment. At 12\u2010month follow up, no disease progression was present.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> In accordance with previous data, this single case underlines the potent activity of alemtuzumab in advanced, chemotherapy\u2010refractory SS.<\/jats:p>","DOI":"10.1046\/j.0902-4441.2004.00169.x","type":"journal-article","created":{"date-parts":[[2003,12,22]],"date-time":"2003-12-22T10:50:16Z","timestamp":1072090216000},"page":"61-63","source":"Crossref","is-referenced-by-count":26,"title":["Successful treatment of chemotherapy\u2010refractory S\u00e9zary syndrome with alemtuzumab (Campath\u20101H)"],"prefix":"10.1111","volume":"72","author":[{"given":"O.","family":"Gautschi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Blumenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Streit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Solenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Hunziker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Zenh\u00e4usern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,12,22]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.15.2908"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2247"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200203030-00006"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.1990.tb01767.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1985.tb07383.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-200011000-00010"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2802"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.0902-4441.2004.00169.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.0902-4441.2004.00169.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.0902-4441.2004.00169.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T12:46:02Z","timestamp":1697201162000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.0902-4441.2004.00169.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12,22]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["10.1046\/j.0902-4441.2004.00169.x"],"URL":"https:\/\/doi.org\/10.1046\/j.0902-4441.2004.00169.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12,22]]}}}